B+
Bull case
25%
Probability
Target price
$595.88
+108.3% vs current
ALNY
AlnylamBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$397.25
+38.8% vs current
B-
Bear case
20%
Probability
Target price
$238.35
-16.7% vs current
AI sentiment snapshot
Latest data as of 2025-12-31
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+94.7
Score
AI commentary
Market tone is mixed: investors balance strong enthusiasm for RNAi platform potential with near-term binary clinical and commercialization risks [#IR]. Recent communications emphasize commercial execution and upcoming data windows, tempering exuberance into guarded optimism [#PR]. Overall commentary skews neutral-to-cautious pending confirmed readouts.
RankAlpha Sentiment AI - 2025-12-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31catalystNext quarterly earnings releaseHigh impact
Quarterly earnings and management commentary may shift near-term sentiment; date estimated conservatively as a short-term catalyst (assumed quarterly cycle) [#IR].
2026-06-30eventMid‑stage/late‑stage clinical data readout (assumed window end)High impact
Potential program readouts or interim analyses could materially affect valuation; date uses conservative window end assumption when exact public timing is not disclosed [#PR].
2026-12-31catalystCommercial uptake and label expansion progressHigh impact
Longer‑term adoption of approved RNAi medicines and any label expansions or new approvals drive upside; conservative long horizon used.
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-31 • Updated nightlySource: Internal modelMethodology